Citations

Clear

3030 citation(s) found for "Susan, M".

When Is a Critically Ill Cirrhotic Patient Too Sick to Transplant? Development of Consensus Criteria by a Multidisciplinary Panel of 35 International Experts
Blasi, Annabel , Lerut, Jan , Fernández, Javier , Findlay, James Y. , Fondevila, Constantino , Jaber, Samir , Karvellas, Constantine , Kronish, Kate, Laleman, Wim , Laterre, Pierre François, Levesque, Éric , Mandell, M. Susan , Phail, Mark Mc, Olson, Jody C. , Olthoff, Kim M. , Reiberger, Thomas , Reyntjens, Koen , Scatton, Olivier , Simpson, Kenneth J., Subramanian, Ram, Tomescu, Dana , Wagener, Gebhard , McPhail, Mark , Karvellas, Constantine , Reiberger, Thomas , Blasi, Annabel , Weiss, Emmanuel , Saner, Fuat Hakan , Asrani, Sumeet K. , Biancofiore, Gíanni , Durand, François , Francoz, Claire , Gustot, Thierry , Laterre, Pierre‐François , Muiesan, Paolo , Pinna, Antonio Daniele , Saliba, Faouzi , Soubrane, Olivier , Tacke, Frank , Xia, Victor W. , Paugam‐Burtz, Cathérine

Mayo Clinic

Transplantation | June 22, 2020 | Volume: 105 | Issue: 3 | Pages: 561-568

10.1097/tp.0000000000003364 | PMID 32568955 Get It

Background. Critically ill cirrhotic patients are increasingly transplanted, but there is no consensus about futile liver transplantation (LT). Therefore, the decision to delay or deny LT is often extensively debated. These debates arise from different opinions of futility among transplant team members. This study aims to achieve a multinational and multidisciplinary consensus on the definition of futility in LT and to develop well-articulated criteria for not proceeding with LT due to futility. Methods. Thirty-five international experts from anesthesiology/intensive care, hepatology, and transplant surgery were surveyed using the Delphi method. More than 70% of similar answers to a question were necessary to define agreement. Results. The panel recommended patient and graft survival at 1 year after LT to define futility. Severe frailty and persistent fever or <72 hours of appropriate antimicrobial therapy in case of ongoing sepsis were considered reasons to delay LT. A simple assessment of the number of organs failing was considered the most appropriate way to decide whether LT should be delayed or denied, with respiratory, circulatory and metabolic failures having the most influence in this decision. The thresholds of severity of organ failures contraindicating LT for which a consensus was achieved were a Pa o 2 /FiO2 ratio<150 mm Hg, a norepinephrine dose >1 μg/kg per minute and a serum lactate level >9 mmol/L. Conclusions. Our expert panel provides a consensus on the definition of futile LT and on specific criteria for postponing or denying LT. A framework that may facilitate the decision if a patient is too sick for transplant is presented.
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
Vogelbaum, Michael A. , Krivosheya, Daria, Borghei‐Razavi, Hamid , Sanai, Nader , Weller, Michael , Wick, Wolfgang , Reardon, David A. , Wen, Patrick Y. , Bent, Martin J. van den , Chang, Susan M. , Weller, Michael , van den Bent, Martin J , Wick, Wolfgang , Borghei-Razavi, Hamid , Soffietti, Riccardo , Aghi, Manish Kumar , Galanis, Evanthia , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | June 19, 2020 | Volume: 22 | Issue: 11 | Pages: 1568-1579

10.1093/neuonc/noaa149 | PMID 32598442 Get It

Abstract Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics are currently available, and much effort has been expended to identify new drugs capable of slowing tumor progression. The phase 0 trial design was developed to facilitate early identification of promising agents for cancer that should undergo accelerated approval. This design features an early in-human study that enrolls a small number of patients who receive subtherapeutic doses of medication with the goals of describing pharmacokinetics through drug blood level measurements and determining intratumoral concentrations of the investigational compound as well as pharmacodynamics by studying the biochemical and physiological effects of drugs. In neuro-oncology, however, the presence of the blood–brain barrier and difficulty in obtaining brain tumor tissue warrant a separate set of considerations. In this paper, we critically reviewed the protocols used in all brain tumor related in-human phase 0 and phase 0–like (“window of opportunity”) studies between 1993 and 2018, as well as ongoing clinical trials, and identified major challenges in trial design as applied to central nervous system tumors that include surgical specimen collection and storage, brain tumor drug level analysis, and confirmation of drug action. We therefore propose that phase 0 trials in neuro-oncology should include (i) only patients in whom a resection of the tumor is planned, (ii) use of clinical doses of an investigational agent, (iii) tissue sampling from enhancing and non-enhancing portions of the tumor, and (iv) assessment of drug-specific target effects. Standardization of clinical protocols for phase 0/window of opportunity studies can help accelerate the development of effective treatments for glioblastoma.
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain
Carroll, C. Patrick , Edwards-Elliott, Ronisha, Glassberg, Jeffrey , Hurley, Robert W. , Kutlar, Abdullah , Seisa, Mohamed O. , Stinson, Jennifer , Strouse, John J. , Yusuf, Fouza, Zempsky, William T. , Seisa, Mohamed, Hurley, Robert W , Brandow, Amanda M. , Creary, Susan Elizabeth , Lang, Eddy

Mayo Clinic

Blood Advances | June 19, 2020 | Volume: 4 | Issue: 12 | Pages: 2656-2701

10.1182/bloodadvances.2020001851 | PMID 32559294 Get It

Background: The management of acute and chronic pain for individuals living with sickle cell disease (SCD) is a clinical challenge. This reflects the paucity of clinical SCD pain research and limited understanding of the complex biological differences between acute and chronic pain. These issues collectively create barriers to effective, targeted interventions. Optimal pain management requires interdisciplinary care. Objective: These evidence-based guidelines developed by the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in pain management decisions for children and adults with SCD. Methods: ASH formed a multidisciplinary panel, including 2 patient representatives, that was thoroughly vetted to minimize bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic reviews. Clinical questions and outcomes were prioritized according to importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel reached consensus on 18 recommendations specific to acute and chronic pain. The recommendations reflect a broad pain management approach, encompassing pharmacological and nonpharmacological interventions and analgesic delivery. Conclusions: Because of low-certainty evidence and closely balanced benefits and harms, most recommendations are conditional. Patient preferences should drive clinical decisions. Policymaking, including that by payers, will require substantial debate and input from stakeholders. Randomized controlled trials and comparative-effectiveness studies are needed for chronic opioid therapy, nonopioid therapies, and nonpharmacological interventions.
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Talhouk, Aline , Wang, Chen , Budden, Timothy , Kommoss, Stefan , Leong, Huei San, Intermaggio, Maria P., Nazeran, Tayyebeh M., Volchek, Mila, Elatre, Wafaa, Chow, Veronica, Sudderuddin, Hanwei , Mackenzie, Robertson, Leong, Samuel C.Y., Liu, Geyi, Johnson, Dustin, Chen, Billy, Group, AOCS, Alsop, Jennifer , Banerjee, Susana , Bodelón, Clara , Brand, Alison H. , Brinton, Louise A. , Carney, Michael E. , Chiew, Yoke-Eng , Cushing‐Haugen, Kara L. , Ennis, Darren , Fereday, Sián , Fortner, Renée T. , Greene, Casey S. , Hendley, Joy , Hernandez, Brenda Y. , Herpel, Esther , Jimenez‐Liñan, Mercedes , Karpinskyj, Chloe , Keeney, Gary L., Kennedy, Catherine J. , Köbel, Martin , Koziak, Jennifer M. , Lester, Jenny , Lewsley, Liz-Anne , Lissowska, Jolanta , Luk, Hugh, Mahner, Sven� , McNeish, Iain A. , Menkiszak, Janusz , Nevins, Nikilyn, Osório, Ana , Oszurek, Oleg, Pearce, Celeste Leigh , Pike, Malcolm C. , Piskorz, Anna , Rhenius, Valerie , Rodríguez‐Antona, Cristina , Sharma, Raghwa , Silva, Dilrini De , Singh, Naveena , Sinn, Hans‐Peter , Slamon, Dennis J. , Song, Honglin , Steed, Helen , Stronach, Euan A. , Thompson, Pamela J., Tołoczko, Aleksandra, Trabert, Britton , Traficante, Nadia , Tseng, Chiu-Chen , Widschwendter, Martin , Winterhoff, Boris , Beeghly‐Fadiel, Alicia, Brown, Robert , Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , DeFazio, Anna , Fasching, Peter A. , García, María J. , Gayther, Simon A. , Goodman, Marc T. , Henderson, Michelle J. , Kelemen, Linda E. , Menon, Usha , Oršulić, Sandra , Wentzensen, Nicolas , Wu, Anna H. , Schildkraut, Joellen M. , Rossing, Mary Anne, Konecny, Gottfried E. , Huntsman, David G. , Huang, Ruby Yun‐Ju , Goode, Ellen L. , Ramus, Susan J. , Bowtell, David D.L. , Anglesio, Michael S. , George, Joshy , Wang, Chen , Tan, Tuan Zea , Behrens, Sabine , Bodelon, Clara , Brinton, Louise A , Fortner, Renée T , García-Donas, Jesús , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Greene, Casey S , Haluska, Paul , Harris, Holly R , Kaufmann, Scott H , Kennedy, Catherine J , Köbel, Martin , Koziak, Jennifer M , Lissowska, Jolanta , McNeish, Iain A , Menkiszak, Janusz , Hinsley, Samantha , Pike, Malcolm C , Rodríguez-Antona, Cristina , Sinn, Peter , Trabert, B , Widschwendter, Martin , Winham, Stacey J , Brenton, James D , Brown, Robert , Chang-Claude, Jenny , Fazio, Anna de , Fasching, Peter A , Kelemen, Linda E , Menon, Usha , Pharoah, Paul D P , Ramus, Susan J , Doherty, Jennifer A , Anglesio, Michael S , Chenevix-Trench, Georgia , Brand, Alison H , Ennis, Darren P , Traficante, Nadia , Bowtell, David D , Fereday, Sian , Hernandez, Brenda Y , Steed, Helen , Goodman, Marc T , Nevins, Nikilyn , George, Joshy , Chiu, Derek S , Chen, Stephanie , Gilks, C. Blake , Bentley, Rex C. , Senz, Janine , Lum, Amy M. , Group, AOCS, Behrens, Sabine , Cybulski, Cezary , García-Donás, Jesús , Glasspool, Rosalind , Goranova, Teodora , Harris, Holly R. , Kaufmann, Scott H. , Larson, Melissa C. , Lubiński, Jan , Macintyre, Geoff , Palacios, José , Ray-Coquard, Isabelle L. , Sherman, Mark E. , Wilkens, Lynne R. , Winham, Stacey J. , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Berchuck, Andrew , Brenton, James D. , Gronwald, Jacek , Karlan, Beth Y. , Pharoah, Paul D.P. , Doherty, Jennifer A.

Mayo Clinic

Clinical Cancer Research | June 17, 2020 | Volume: 26 | Issue: 20 | Pages: 5411-5423

10.1158/1078-0432.ccr-20-0103 | PMID 32554541 Get It

Abstract Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features. Experimental Design: Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting. Results: Gene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with &gt;95% accuracy that was maintained in all analytic and biological validations. Conclusions: We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications. See related commentary by McMullen et al., p. 5271
When is the Best Time to Initiate Peri-operative Heparin Therapy in General Surgery Patients? A Risk-Benefit Dilemma
Greenlee, Susan M., Farley, David R. , Rostambeigi, Nassir , Huebner, Marianne

Mayo Clinic

The American Surgeon™ | June 17, 2020 | Volume: 77 | Issue: 11 | Pages: 1539-1545

10.1177/000313481107701147 Get It

We sought optimal timing for heparin therapy in general surgery (GS) patients. From 2001 to 2008, 95 GS patients with documented thromboembolic events (TE) were identified and compared with matched controls (age, gender, type of operation, date of operation, malignancy, and body mass index [BMI]). Timing of heparin therapy, characteristics of TE or bleeding events, and risk factors for TE were collected. Mean age (57 years), BMI (33 kgM-2), gender (55% male), malignancy (53%), and duration of operation (204 vs 191 minutes, P = not significant) were similar in both groups. Peri-operative (within 24 hours) heparin administration (study 56% vs control 64%, P = 0.2) was no different. Preoperative therapy was more common in the control group (77% vs 51%, P = 0.001). The regression model showed a protective effect for heparin if given preoperatively (odds ratio = 0.37, P = 0.047) with no effect if started >10 hours from incision. Mean blood transfusion (97 and 106 mL) and hemorrhagic events (4.5% and 5%) were similar in both groups ( P = not significant). Median (range) length of hospital stay and mortality was higher in TE cases [19 (0-201) vs 6 (0-66) days, 11 vs 2 mortality in 100-person-years ( P < 0.05)]. Heparin administration before GS is associated with >2-fold reduction in TE. The optimal time to start heparin seems to be 1 to 10 hours before the time of incision.
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
Song, Honglin , Dicks, Ed , Intermaggio, Maria P., Chenevix‐Trench, Georgia , Bowtell, David D.L. , Traficante, Nadia , Group, AOCS, Hosking, Karen, Piskorz, Anna , Oudenhove, Elke Van , Doherty, J.A. , Rossing, Mary Anne, Duerst, Matthias, Dörk, Thilo , Bogdanova, Natalia , Moysich, Kirsten B. , Odunsi, Kunle , Ness, Roberta B., Lester, Jenny, Pujara, Miguel Angel, Cunningham, Julie M. , Hildebrandt, Michelle, Huff, Chad , Li, Donghui , Wu, Xifeng , Yu, Yao , Levine, Douglas A. , Schildkraut, Joellen M. , Riggan, Marjorie J. , Webb, Penelope M. , Group, OPAL Study, Jakubowska, Anna , Alsop, Jennifer , Harrington, Patricia, Chan, Isaac H Y , Menon, Usha , Pearce, Celeste Leigh, Wu, Anna H. , Fazio, Anna de , Kennedy, Catherine J. , Goode, Ellen L. , Ramus, Susan J. , Gayther, Simon A. , DeFazio, Anna , Cunningham, Julie, Vierkant, Robert, Huff, Chad , Cybulski, Cezary , Pharoah, Paul D P , Dörk, Thilo , Ramus, Susan J , Webb, Penelope M , Menon, Usha , Moysich, Kirsten , Kennedy, Catherine J , Jakubowska, Anna , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Traficante, Nadia , Bowtell, David D , Tyrer, Jonathan P. , Group, AOCS, Brenton, James D. , Goranova, Teodora , Harris, Holly R. , Modugno, Francesmary , Karlan, Beth Y. , Jensen, Allan , Kjær, Susanne K. , Høgdall, Estrid , Campbell, Ian , Lázaro, Conxi , Vierkant, Robert A. , Winham, Stacey J. , Permuth, Jennifer B. , Berchuck, Andrew , Cybulski, Cezary , Gronwald, Jacek , Lubiński, Jan , Pharoah, Paul D.P.

Mayo Clinic

Journal of Medical Genetics | June 16, 2020 | Volume: 58 | Issue: 5 | Pages: 305-313

10.1136/jmedgenet-2019-106739 | PMID 32546565 Get It

Purpose The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare deleterious germline variants in a set of candidate genes. Methods We sequenced the coding region of 54 candidate genes in 6385 invasive EOC cases and 6115 controls of broad European ancestry. Genes with an increased frequency of putative deleterious variants in cases versus controls were further examined in an independent set of 14 135 EOC cases and 28 655 controls from the Ovarian Cancer Association Consortium and the UK Biobank. For each gene, we estimated the EOC risks and evaluated associations between germline variant status and clinical characteristics. Results The ORs associated for high-grade serous ovarian cancer were 3.01 for PALB2 (95% CI 1.59 to 5.68; p=0.00068), 1.99 for POLK (95% CI 1.15 to 3.43; p=0.014) and 4.07 for SLX4 (95% CI 1.34 to 12.4; p=0.013). Deleterious mutations in FBXO10 were associated with a reduced risk of disease (OR 0.27, 95% CI 0.07 to 1.00, p=0.049). However, based on the Bayes false discovery probability, only the association for PALB2 in high-grade serous ovarian cancer is likely to represent a true positive. Conclusions We have found strong evidence that carriers of PALB2 deleterious mutations are at increased risk of high-grade serous ovarian cancer. Whether the magnitude of risk is sufficiently high to warrant the inclusion of PALB2 in cancer gene panels for ovarian cancer risk testing is unclear; much larger sample sizes will be needed to provide sufficiently precise estimates for clinical counselling.
Diffuse alveolar hemorrhage due to Legionella pneumophila serogroup 3
Chowdhury, Arnab , Khan, Syed Anjum , Haugh, Susan

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | June 15, 2020 | Volume: 10 | Issue: 3 | Pages: 262-264

10.1080/20009666.2020.1767274 | PMID 32850075 Get It

The Relationship Between Residents’ Perceptions of Residency Program Leadership Team Behaviors and Resident Burnout and Satisfaction
Winters, Richard C. , Moeschler, Susan M. , Stelling, Brianna E. Vaa , Dozois, Eric J. , Satele, Daniel , Dyrbye, Liselotte N. , Leep Hunderfund, Andrea N, Vaa Stelling, Brianna E, Satele, Daniel V, Hunderfund, Andrea N. Leep , West, Colin P.

Mayo Clinic

Academic Medicine | June 10, 2020 | Volume: 95 | Issue: 9 | Pages: 1428-1434

10.1097/acm.0000000000003538 | PMID 32520754 Get It

Purpose To explore the relationship between residents’ perceptions of residency program leadership team behaviors and resident burnout and satisfaction. Method In February 2019, the authors surveyed all residents across the 77 graduate medical education training programs at Mayo Clinic’s multiple sites. Survey items measured residents’ perceptions of program director and associate program director behaviors (using a composite residency program leadership team score), resident burnout, and resident satisfaction with the program and organization. Multivariable logistic regression was performed to evaluate relationships between these variables at the individual resident (adjusting for age, sex, postgraduate training year, program location, and specialty) and program (including only programs with at least 5 respondents) levels. Results Of the 1,146 residents surveyed, 762 (66.5%) responded. At the individual resident level, higher composite leadership team scores were associated with lower emotional exhaustion and depersonalization and higher overall satisfaction with the residency program and organization (all P < .001). In adjusted logistic regression models, each 1-point gain in composite leadership team score was associated with 9% lower odds of burnout, 20% higher odds of program satisfaction, and 19% higher odds of satisfaction with the organization (all P < .001). At the residency program level, higher mean composite leadership team scores were associated with a lower rate of burnout (r = −0.35, P = .03) and higher program and organization satisfaction (r = 0.67 and 0.74, respectively, both P < .001). Conclusions The behaviors of residency program leadership teams influence residents’ burnout and satisfaction. Additional studies are needed to determine if leadership training results in improved resident well-being and satisfaction.
Beyond Revision Surgery: Work‐Up and Interventional Treatments for the Painful Total Knee Arthroplasty
Hagedorn, Jonathan M. , Wooster, Benjamin M., Moeschler, Susan M. , Orhurhu, Vwaire , Trousdale, Robert T. , Hunt, Christine L., Orhurhu, Vwaire , Hagedorn, Jonathan M , Hunt, Christine

Mayo Clinic

Pain Practice | June 9, 2020 | Volume: 20 | Issue: 8 | Pages: 929-936

10.1111/papr.12924 | PMID 32515912 Get It

AbstractTotal knee arthroplasty is a common and successful treatment modality for knee arthritis that is refractory to conservative management strategies. Over 600,000 arthroplasties are performed per year in the United States, and this number is expected to increase in the coming years. Unfortunately, 8% to 34% of patients experience chronic pain after having a total knee arthroplasty. These patients should undergo an appropriate work‐up by the orthopedic surgeon, but many times a surgical problem is not uncovered. In these situations, a thorough and specific plan for pain management should be sought. In this article, we outline the work‐up of a painful total knee arthroplasty. Then we provide a thorough review of interventional pain management strategies and highlight the pertinent literature. Lastly, we hypothesize future developments in the field that may provide better outcomes for patients suffering from painful total knee arthroplasty.